# 此協議是中國生技產業在外國藥廠日益關注下的最新合作案之一，標誌著禮來自身合作範圍的擴大。

*biotech · news · 2026-06-01 · Reuters*

## Key points

- 禮來與海思科子公司簽署創新藥物項目的授權協議。
- 禮來取得海思科部分資產的全球權利，但不包括大中華區域。
- 海思科子公司將從禮來獲得高達8700萬美元的前期及近期付款。
- 該協議可能為海思科子公司帶來約30億美元的額外里程碑付款。

The deal is ⁠one of the latest for China's ​biotech sector amid increasing interest from foreign ​drugmakers in local businesses' development pipelines, and marks an expansion of collaborations for Lilly itself. Sign up here. The latest deal with ‌the ⁠Haisco unit covers innovative drug projects, Haisco said in a filing to the Shenzhen stock exchange. Under the terms, Lilly ​will secure ​worldwide rights ⁠to select Haisco unit assets outside mainland China, Hong Kong, ​Macau and Taiwan. The unit is ​eligible ⁠to receive up to $87 million in upfront and near-term payments, and up to ⁠about $3 ​billion in additional payments ​tied to clinical, regulatory and commercialisation-related milestones. Reporting by Andrew ​Silver in Hangzhou, Editing by Louise Heavens

**Companies:** Lilly, Haisco
**Countries:** China

[Read the full story on Reuters](https://www.reuters.com/legal/litigation/unit-chinas-haisco-eli-lilly-sign-collaboration-licensing-deals-2026-06-01/)

---

Canonical: https://newsio.io/zh-TW/n/af4115d6-5ac4-409a-be62-8d5172425eff/
Summarized by Newsio from Reuters. https://newsio.io/how-it-works